Status
ACTIVE
Global HQ
San Francisco, United States
Countries of investment
- USA
Investment stages
- Pre-Seed
- Seed
Industries
- Biotechnology
- Health Tech
- AI
- Sustainable Energy
About
IndieBio is the premier early-stage biotech accelerator program that empowers scientists to transform innovative ideas into successful ventures. Offering $250,000 in funding, state-of-the-art lab space, and comprehensive mentorship, IndieBio fosters a collaborative environment where scientific discovery meets entrepreneurial spirit. As a key initiative of SOSV, IndieBio champions a diverse array of biotechnology startups, focusing on areas such as health, sustainability, and agriculture to drive impactful change in the world. With a strong network of industry experts and investors, IndieBio is dedicated to cultivating the next generation of breakthrough companies that address pressing global challenges.
IndieBio is the premier early-stage biotech accelerator program that empowers scientists to transform innovative ideas into successful ventures. Offering $250,000 in funding, state-of-the-art lab space, and comprehensive mentorship, IndieBio fosters a collaborative environment where scientific discovery meets entrepreneurial spirit. As a key initiative of SOSV, IndieBio champions a diverse array of biotechnology startups, focusing on areas such as health, sustainability, and agriculture to drive impactful change in the world. With a strong network of industry experts and investors, IndieBio is dedicated to cultivating the next generation of breakthrough companies that address pressing global challenges.
Investment Thesis
IndieBio invests in early stage biotechnology companies, providing multistage capital to support groundbreaking ideas in various sectors where biology can be used to engineer novel solutions.
Manager's Experience
With a strong background in biotechnology and life sciences, the fund manager boasts a robust portfolio comprising over 30 investments across North America and Europe. Specializing in early-stage ventures, they have led numerous successful rounds, with notable exits highlighting their strategic, operator-first approach. Their focus on companies innovating in therapeutics and medical devices illustrates a commitment to advancing healthcare solutions. Through diligent analysis and a hands-on investment style, they effectively drive growth and enhance value within their portfolio.
Team
Steven Oconnell
Po Bronson
Po Bronson
Aviel Even
Maya Lockwood
Kristrun Hjartar
Helen Cao
Elsa Jungman
Parikshit Sharma